SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 120 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2014. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2015 | $316,538,000 | -11.3% | 3,245,542 | -15.6% | 1.72% | -2.7% |
| Q4 2014 | $356,972,000 | +32.2% | 3,847,094 | -2.0% | 1.77% | +42.2% |
| Q3 2014 | $270,099,000 | -26.8% | 3,927,006 | +11.5% | 1.24% | -16.1% |
| Q2 2014 | $369,001,000 | +43.8% | 3,521,000 | +13.8% | 1.48% | +46.8% |
| Q1 2014 | $256,626,000 | +23.3% | 3,093,000 | -3.9% | 1.01% | +26.9% |
| Q4 2013 | $208,204,000 | +2.0% | 3,217,000 | -0.2% | 0.80% | -3.3% |
| Q3 2013 | $204,111,000 | +95.5% | 3,224,000 | +29.7% | 0.82% | +79.9% |
| Q2 2013 | $104,382,000 | – | 2,485,288 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 10,660,432 | $989,182,000 | 10.10% |
| BB BIOTECH AG | 1,130,476 | $104,897,000 | 3.40% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 80,000 | $7,423,000 | 3.31% |
| Opus Point Partners Management, LLC | 20,002 | $1,856,000 | 1.84% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,847,094 | $356,972,000 | 1.77% |
| SECTORAL ASSET MANAGEMENT INC | 363,884 | $33,765,000 | 1.52% |
| Cormorant Asset Management, LP | 100,000 | $9,279,000 | 1.43% |
| Tekla Capital Management LLC | 223,020 | $20,694,000 | 0.97% |
| Lamond Capital Partners LLC | 15,390 | $1,428,000 | 0.94% |
| Squarepoint Ops LLC | 6,700 | $622,000 | 0.60% |